Close

Match-making to find a new treatment for MND

Reading Time: 3 minutes Translating recent scientific discoveries in MND into the development of new and better treatments is a major challenge we face. To facilitate this process within the UK, we’ve recently played a role in match-making a key UK academic neuroscience department and a commercial organisation. Pharmaceutical industry – the big, the small and the CROs Discovery…

Come fly with me

Reading Time: 3 minutes Although millions of years of evolution separate humans from insects, a tiny fruit fly called Drosophila melanogaster has been one of the most extensively studied organisms for more than a century, leading to many advances in research. But why are flies so useful? And can we really learn anything from them? Why fly? It is…

One week on – Reflections on my first experience of the International Symposium on ALS/MND

Reading Time: 2 minutes Our recent blog articles describe lots of fascinating science and the progress in the care and treatment of MND/ALS that was presented at the symposium.  Personally, another really positive aspect was the opportunity to meet some of the researchers face-to-face. This included several senior scientists and clinicians whose work we support, some of whom gave lectures…

Inspired by viruses

Reading Time: < 1 minute I attended a fantastic talk this morning in the session on ‘Translational Strategies’. This session is all about moving laboratory ideas for new treatments for MND into the clinic to test them in clinical trials. The first talk was given by Battaglia, based at the University of Sheffield. In this presentation, he described a multidisciplinary…

‘Hello’ from the newest member of the team

Reading Time: 2 minutes As the newest recruit to the Research Development Team, I have been asked to let everyone know a bit more about me.  Previously I was a Medicinal Chemist working for GlaxoSmithKline (GSK) for almost 20 years.  In that time I “survived” two corporate mergers and worked at three different research sites.  For almost a third…